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Symptoms of atopic asthma often decrease or even seem to disap-
pear around puberty. The aim of this study was to investigate
whether this so-called clinical remission is accompanied by remis-
sion of airway inflammation, since symptoms relapse in a substan-
tial proportion of subjects later in life. To assess indicators of in-
flammation and/or structural damage of the airways, exhaled
nitric oxide (eNO) and bronchial responsiveness to adenosine-
5
 
9
 
-monophosphate (AMP) and methacholine (MCh) were deter-
mined in 21 subjects in clinical remission of atopic asthma. Clinical
remission was defined as complete absence of symptoms of
asthma without the use of any medication in the year preceding
the study. Results were compared with those of 21 patients with
current asthma and 18 healthy control subjects. We found signifi-
cantly higher eNO values in the remission group than in healthy
controls (geometric mean, 18.9 and 1.0 ppb, respectively; p 
 
,
 
 0.001)
whereas eNO values of the remission group and those of the subjects
with current asthma (geometric mean, 21.9 ppb) were similar (p 
 
5
 
0.09). The responsiveness to both AMP and MCh of subjects in clinical
remission was significantly higher as compared with responsiveness
of healthy controls, and lower than responsiveness of subjects
with current asthma. A significant correlation could be established
between eNO and responsiveness to AMP, but not between eNO
and responsiveness to MCh. The results of this study are suggestive
of persistent airway inflammation during clinical remission of atopic
asthma. We speculate that subclinical inflammation is a risk factor
for asthma relapse later in life, and that eNO and responsiveness
to both AMP and MCh can be used as different, noninvasive indices
of the inflammatory process of the airways.
 
Asthma is a chronic inflammatory disorder of the airways,
characterized by cellular infiltration, cellular activity, and cell
damage, but also by edema, vascular leakage, and hypertrophy/
hyperplasia of resident cells, as there are goblet cells and
smooth muscles. Structural changes of the airway walls occur
early in the course of the disease (1, 2). Epidemiological studies
have shown that symptoms of atopic asthma often begin in
early childhood and improve or seem to disappear around pu-
berty (3, 4). However, a considerable proportion of individuals
with asthma in “clinical remission” will have a relapse later in
life (3). Several studies have shown spirometric abnormalities
and bronchial hyperresponsiveness (BHR) to methacholine
(MCh) or cold air challenge during clinical remission of asthma
(5, 6). It is unknown whether these functional abnormalities,
which are supposed to be indicative of asthma severity with re-
spect to symptomatic asthma, reflect persistent airway inflam-
mation or merely indicate residual airway damage. These con-
siderations seem to be important, as it is reasonable to believe
that persistent airway inflammation during clinical remission of
atopic asthma has substantial impact on the risk of relapse at a
later age. The question arises whether other available noninva-
sive physiological techniques can give information about the
presence of an ongoing inflammatory process.
Nitric oxide synthase (NOS) is a newly identified enzyme
system active in airway epithelial and endothelial cells, mac-
rophages, neutrophils, mast cells, autonomic neurons, smooth
muscle cells, and fibroblasts. The existence of an inducible
form of NOS (iNOS) in human lungs suggests that increased
production of NO, probably induced by cytokines, may be rel-
evant to the pathology of asthma (7). Many studies concerning
atopic asthma demonstrate elevated NO levels in exhaled air
(8, 9). Furthermore, exhaled NO (eNO) levels are decreased
by antiinflammatory therapy, which offers opportunities to mon-
itor compliance with and effectiveness of treatment (10). The
measurement of eNO can be performed repeatedly, even in
children and patients with severe airflow obstruction, in whom
invasive techniques are not feasible or desirable. Studies re-
garding eNO reported a weak relationship between eNO levels
and BHR (11, 12), indicating the complexity of mechanisms in-
volved in atopic asthma. The usefulness and specificity of eNO
values with respect to the monitoring of airway inflammation
in atopic asthma are still under investigation.
BHR is one of the hallmarks of asthma and is often used as
an indicator of asthma severity. Several studies have shown a
significant correlation between BHR and airway inflammation
in symptomatic asthma (13–15). The degree of airway respon-
siveness can be assessed with a variety of inhaled stimuli, such
as MCh or adenosine-5
 
9
 
-monophosphate (AMP). MCh in-
duces airway constriction via direct stimulation of the musca-
rin receptors on airway smooth muscle cells. AMP, on the
other hand, causes airway narrowing mainly through indirect
mechanisms, in particular stimulation of mast cells and activa-
tion of neuronal reflexes in the lung (13). Since mast cells are
believed to play a predominant role in atopic asthma, the
bronchial response to AMP, in addition to the response to
MCh, may serve as indicator of the inflammatory process.
The aim of this study was to measure eNO values and bron-
chial responsiveness to MCh and AMP, each reflecting dis-
tinct parts of the inflammatory process in the airways, in previ-
ously well-documented atopic asthmatic adolescents who were
in clinical remission for more than one year. Data were com-
pared with data on adolescents with current asthma and healthy
control subjects.
 
METHODS
 
Subjects
 
Adolescents, 18–25 yr of age, with atopic asthma were selected from
the Sophia Children’s Hospital (Rotterdam, The Netherlands) dis-
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charged patient files. Clinical remission was assumed if subjects re-
ported complete absence of cough, wheezing, and breathlessness at
rest and on exertion and had not taken any medication in order to
control asthmatic symptoms for at least 12 mo before the study.
Twenty-one eligible subjects in remission were included, and com-
pared with 21 patients with asthma who had persistent symptoms at
least once a month in the year preceding the study, and used inhaled
 
b
 
2
 
-agonists on demand in order to relieve symptoms. All subjects had
a history of wheezing and chest tightness and were previously diag-
nosed as having atopic asthma according to American Thoracic Soci-
ety (ATS) criteria (16). In the past, all had a provocation dose/con-
centration of MCh or histamine producing a 20% fall in FEV
 
1
 
 of 
 
<
 
150 
 
m
 
g (dosimeter method) or 
 
<
 
 8 mg ml
 
2
 
1
 
 (2-min tidal breathing
method), and/or had an FEV
 
1
 
 reversibility 
 
>
 
 12% of predicted nor-
mal value. All had evidence of atopy defined by radioallergosorbent
test (RAST) Class 2 or higher for at least one common airborne aller-
gen. Participating subjects were lifelong nonsmokers, in stable clinical
condition, and did not take inhaled steroids, including nasal steroids,
or antiallergic medication such as cromoglycate and antihistamines
for at least 1 yr before the study.
Eighteen healthy nonsmoking young adult volunteers were re-
cruited via advertisement and served as control subjects. They had a
negative personal and first-degree family history of asthma and atopy.
Common exclusion criteria were an inability to perform lung function
tests reproducibly, perennial rhinitis, and other illnesses that may af-
fect lung function. None of the subjects in the study reported symp-
toms of respiratory infection in the month before the study. The study
was approved by the Medical Ethics Committee of the Erasmus Uni-
versity and University Hospital Rotterdam.
 
Study Design
 
We performed a cross-sectional study with three visits on separate
days. At the first visit, subjects gave informed written consent and
were asked about asthmatic symptoms and requirement for rescue
medication during the past year, especially to avoid the inclusion of
subjects with mild symptoms of asthma in the remission group. For
the same reason, subjects were asked to complete Juniper’s Quality of
Life Questionnaire (17), which was verified by the investigator on hid-
den minor symptoms. Also, physical examination was performed and
eNO and PD
 
20
 
MCh (provocative concentration of MCh causing a
20% fall in FEV
 
1
 
) determined. At Visit 2, scheduled at least 1 d after
Visit 1, subjects underwent an AMP challenge test. At Visit 3, sched-
uled at least 3 d after Visit 2, FEV
 
1
 
 and FEV
 
1
 
 reversibility were
tested. The sequence and intervals were chosen to avoid any influence
of the AMP challenge on MCh responsiveness and/or on FEV
 
1
 
 (18).
The maximal time allowed between Visits 1 and 3 was 3 wk.
 
Spirometry
 
Short acting 
 
b
 
2
 
-agonists were not allowed within 8 h before the test.
Flow–volume curves were obtained with a Lilly-type pneumotachograph
(Masterlab Jaeger, Würzburg, Germany). The best of three reproducible
recordings of FEV
 
1
 
 was expressed as percentage of predicted normal
and used for analysis. Reversibility was tested by measuring FEV
 
1
 
 before
and 20 min after inhalation of 1 mg of terbutaline powder (Bricanyl
Turbuhaler; Astra, Lund, Sweden), and expressed as increase in per-
centage of predicted normal.
 
Nitric Oxide
 
On the basis of the recommendations of the European Respiratory
Society Task Force (19), eNO was measured in exhaled air by means
of chemiluminescence (model 280 nitric oxide analyzer; Sievers, Boul-
der, CO) with a sensitivity of 0.1 ppb and a detection range of 
 
,
 
 0.1–
500,000 ppb. The sampling flow was 0.2 L/min and the response time
0.2 s. Data were displayed continuously on a PC screen, and stored in
a computer with a sample frequency of 20 Hz for later analysis. The
analyzer was calibrated regularly according to the manufacturer guide-
lines, employing certified calibration gases containing 0 ppb, 100 ppb,
and 9 ppm NO (Hoekloos, Barendrecht, The Netherlands). The mea-
surement circuit consisted of a mouthpiece connected to a two-way
nonrebreathing valve (Hans Rudolph, Kansas City, MO), through
which subjects inhaled ambient air (if ambient NO was 
 
, 
 
10 ppb) or
NO-free medical air (if ambient NO was 
 
. 
 
10 ppb) while seated, not
 
wearing a noseclip. Subjects inhaled to TLC and immediately exhaled
for as long as possible into a tube with an in-line flow resistor (20 cm
H
 
2
 
O L
 
2
 
1
 
 s
 
2
 
1
 
; Hans Rudolph). This was done at a flow corresponding
to 5% of subject vital capacity per second, with the aid of a visual
feedback display. A fine-bore Teflon tube continuously sampled ex-
haled air from a side port situated directly after the mouthpiece to the
analyzer. Water vapor was absorbed by means of an NO-inert filter in
the tube. Airflow was measured with a Lilly-type pneumotachograph
(Masterlab Jaeger) positioned downstream of the resistor. An end-
expiratory plateau of at least 10 s, where flow varied 
 
6 
 
10% of the
target flow, was the end point of the measurement. The test was done
in triplicate and average eNO at the plateau calculated by means of
custom-made software.
 
Methacholine and Adenosine-5
 
9
 
-Monophosphate Challenge
 
Challenge tests were performed at the same time of day (
 
6 
 
1 h) ac-
cording to the dosimeter method validated by Birnie and coworkers
(20). Short-acting 
 
b
 
2
 
-agonists were not allowed within 8 h before the
test. Calibrated DeVilbiss 646 nebulizers (DeVilbiss Health Care,
Somerset, PA) were filled with 3 ml of the appropriate solutions. Sub-
jects inhaled four 5-
 
m
 
l volumes, using a French–Rosenthal dosimeter
(Laboratory for Applied Immunology, Fairfax, VA). After recording
baseline values, the challenge started with inhalation of 0.9% NaCl. If
a patient responded to saline or the lowest concentration of either
MCh or AMP, they were assigned a PD
 
20
 
 value of half the starting
dose. Inhalation provocation tests were performed with doubling con-
centrations of 0.15 to 78.4-mg/ml MCh bromide in phosphate-buff-
ered saline (PBS) or 0.08- to 160-mg/ml AMP in normal saline
(Sigma, St. Louis, MO). Provocative doses causing a 20% fall in FEV
 
1
 
(PD
 
20
 
) from baseline were calculated by means of linear interpolation
of the logarithmic dose–response curve. If FEV
 
1
 
 fell less than 20% of
the prechallenge level at the highest dose administered, twice the
highest dose was arbitrarily used as the PD
 
20
 
 value. An MCh PD
 
20
 
value of 1,000 
 
m
 
g, corresponding approximately to 7.8 
 
m
 
mol cumula-
tive, was considered the cutoff value for bronchial hyperresponsive-
ness to MCh.
 
Peak Expiratory Flow Rate
 
After being instructed by the investigator at Visit 1, the patients re-
corded their peak expiratory flow rate (PEFR) with a Personal Best
peakflow meter (Respironics, Nantes, France) twice daily at home dur-
ing the period between Visit 1 and Visit 3. PEFR was always recorded
before bronchodilatation. Each measurement consisted of three at-
tempts, of which the highest value was used for further analysis.
 
Statistical Analysis
 
Because of their highly skewed distributions, PD
 
20
 
 and eNO values
were analyzed after logarithmic transformation. Mean data were ex-
pressed as geometric mean e
 
6
 
SEM(ln
 
 
 
X)
 
. With respect to PD
 
20
 
 values,
comparisons between groups were made by the Mann–Whitney test
for unpaired samples. Correlation between different tests was made
by the Spearman rank correlation test. The distributions of all other
variables were not significantly different from a standard normal dis-
tribution. Hence, parametric techniques (Student 
 
t
 
 test, Pearson cor-
relation coefficients) were applied. Mean values of these parameters
were expressed as means 
 
6
 
 SEM. A two-tailed p value of less than
0.05 was considered significant. Data were analyzed with the Statisti-
cal Package for the Social Science (SPSS, Chicago, IL) for Windows
version 8.0.
 
RESULTS
 
Sixty subjects completed the study (21 subjects with current
asthma, 21 subjects in clinical remission, and 18 healthy con-
trols). The male-to-female ratio was 15 to 6 in the asthmatic
group, 18 to 3 in the remission group, and 10 to 8 in the control
group. Age did not differ significantly between the groups
(22 
 
6
 
 2 yr in the asthmatic group, 21 
 
6
 
 2 yr in the remission
group, and 24 
 
6
 
 1 yr in the control group). Duration of remis-
sion in the remission group varied from 1 to 12 yr (median, 5 yr).
All subjects of the asthma group and the remission group, and
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two subjects of the control group, had positive RAST tests.
Results of eNO measurement, bronchial provocation tests,
and spirometry are summarized in Table 1.
 
Exhaled NO Values
 
Geometric mean eNO values in the remission group were sig-
nificantly higher than in healthy controls (mean, 18.9 and 1.0
ppb, respectively; p 
 
,
 
 0.001), and slightly but not significantly
lower than those of subjects with asthma (21.9 ppb; p 
 
5
 
 0.09)
(Table 1; Figure 1). Although there seemed to be a trend to-
ward lower eNO values with longer duration of remission, a
significant correlation between these variables could not be
established.
 
Bronchial Challenge Tests
 
In the remission group, 11 of 21 subjects had a PD
 
20
 
MCh of
less than 1,000 
 
m
 
g, compared with none of the control subjects.
Of the subjects with asthma, 19 of 21 showed a PD
 
20
 
MCh
value below this level. PD
 
20
 
MCh values in the remission group
were significantly lower than in the control group (geometric
mean, 751 and 4,954 
 
m
 
g, respectively; p 
 
,
 
 0.001), but higher
than in the asthmatic group (94 
 
m
 
g; p 
 
,
 
 0.001) (Figure 2). The
AMP challenge showed significantly lower PD
 
20
 
AMP values
in the remission group than in the control group (geometric
mean, 5,704 and 10,496 
 
m
 
g, respectively; p 
 
,
 
 0.01), but higher
values in the remission group than in the asthmatic group
(1,110 
 
m
 
g, p 
 
,
 
 0.01) (Figure 3). In subjects in remission and
those with asthma, PD
 
20
 
MCh and PD
 
20
 
AMP were highly cor-
related (r 
 
5
 
 0.72, p 
 
,
 
 0.001). There was a significant inverse
correlation between PD
 
20
 
AMP and eNO (r 
 
5
 
 
 
2
 
0.51; p 
 
5
 
0.001), while no correlation could be established between
PD
 
20
 
MCh and eNO (r 
 
5
 
 
 
2
 
0.25; p 
 
5
 
 0.1). There was no signifi-
cant relationship between formerly and currently assessed
bronchial responsiveness, or between duration of remission
and bronchial responsiveness.
 
Spirometry and PEFR
 
Baseline FEV
 
1
 
 values, expressed as percentage of predicted
normal value, were significantly reduced in subjects in remis-
sion compared with healthy control subjects (mean, 93 and
105%, respectively; p 
 
5
 
 0.02). No significant difference could
be detected between subjects in remission and subjects with
asthma (mean, 88%). Reversibility in FEV
 
1
 
 was significantly
different (p 
 
,
 
 0.02) between the three groups (mean, 11, 7,
and 4% in subjects with asthma, subjects in remission, and
healthy control subjects, respectively). Mean diurnal PEFR
variation was 13% in subjects with asthma, 11% in subjects in
 
TABLE 1
EXHALED NO AND LUNG FUNCTION IN SUBJECTS WITH AND WITHOUT
CLINICAL REMISSION OF ASTHMA, AND IN HEALTHY CONTROL SUBJECTS
 
Parameter*
Subjects with
Asthma
(
 
n
 
 
 
5
 
 
 
21
 
)
Subjects in Clinical
Remission of Asthma
(
 
n
 
 
 
5
 
 
 
21
 
)
Healthy Control Subjects
(
 
n
 
 
 
5
 
 
 
18
 
)
eNO, ppb 22e
 
6
 
0.19†
 
14e
 
6
 
0.15 †
 
1e
 
6
 
0.31
 
PD
 
20
 
MCh, 
 
m
 
g 94e
 
6
 
0.37†
 
752e
 
6
 
0.31‡
 
4954e
 
6
 
0
 
PD
 
20
 
AMP, 
 
m
 
g 1110e
 
6
 
0.37†
 
5704e
 
6
 
 0.22§
 
10496e
 
6
 
0
 
FEV
 
1
 
 % pred 88 
 
6
 
 12
 
†
 
93 
 
6
 
 15
 
i
 
105 
 
6
 
 13
Reversibility FEV
 
1
 
, % 11 
 
6
 
 1
 
†
 
7 
 
6
 
 1
 
#
 
4 
 
6
 
 1
Diurnal PEFR variation, % 13 
 
6
 
 2 11 
 
6
 
 1 8 
 
6
 
 1
 
Definition of abbreviations
 
: PD
 
20
 
MCh 
 
5
 
 provocative dose of methacholine causing a 20% fall in FEV
 
1
 
. PD
 
20
 
AMP 
 
5
 
 provocative dose of ad-
enosine-5
 
9
 
-monophosphate causing a 20% fall in FEV
 
1
 
; reversibility FEV1 5 change in FEV1, expressed as increase in percentage of pre-
dicted normal value after administration of 1 mg of terbutaline.
* eNO, PD20MCh, and PD20AMP are expressed as geometric mean e
6SEM(ln X). All other variables are expressed as means 6 SEM.
† p , 0.001 versus healthy controls.
‡ p , 0.001 versus healthy controls and asthmatics.
§ p , 0.01 versus healthy controls and asthmatics.
i p 5 0.02 versus healthy controls.
# p , 0.02 versus healthy controls and asthmatics.
Figure 1. Exhaled NO values of currently asthmatic subjects, of sub-
jects in clinical remission of atopic asthma, and of healthy controls.
Each dot represents one subject. Horizontal bars represent geometric
mean values. The y axis shows NO values logarithmically.
Figure 2. PD20MCh (micrograms, not cumulative) values of currently
asthmatic subjects, of subjects in clinical remission of atopic asthma,
and of healthy controls. Nonresponders are arbitrarily given a value of
twice the highest dose administered. Horizontal bars represent geo-
metric mean values. The y axis shows PD20MCh values logarithmically.
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remission, and 8% in control subjects, and showed no signifi-
cant difference between the groups.
DISCUSSION
In this study, we demonstrated elevated levels of eNO and air-
way hyperresponsiveness to MCh and AMP in adolescents in
long-standing clinical remission of atopic asthma. During re-
mission, eNO levels were almost similar to those found in sub-
jects with current asthma. There was a significant correlation
between eNO values and AMP responsiveness, but not be-
tween eNO values and MCh responsiveness. A significant re-
lationship between duration of remission and degree of abnor-
malities could not be established.
Studies regarding completely symptom-free subjects who
had well-documented atopic asthma in the past are scarce (5).
In our study, subjects were regarded to be in clinical remission
when they reported complete absence of symptoms and were
without treatment for at least 1 yr preceding the study. This
definition was applied to avoid the inclusion of asthmatic sub-
jects with mild symptoms in the remission group. The possibil-
ity that subjects with mild symptoms were included in other
studies on asthma remission cannot be ruled out. In one of
these studies, asthma was considered inactive when subjects
reported no asthma attacks or use of medication during the
preceding year, and were without frequent episodes of short-
ness of breath with wheezing (6). Following this definition of
remission, the investigators reported bronchial hyperrespon-
siveness to MCh with or without airflow obstruction in sub-
jects aged 18–61 yr in remission.
Despite the relatively long median duration of remission,
we found that subjects in clinical remission had significantly
elevated eNO levels, as compared with eNO levels from
healthy controls. Exhaled NO originates from several inflam-
matory cell types in the airways, including epithelial and en-
dothelial cells and macrophages. Whether elevated eNO lev-
els are caused by enhanced activity of inflammatory cells
expressing NOS, potentially driven by inflammatory media-
tors or cytokines, and/or by enhanced diffusion through the
airway wall due to structural damage, remains to be resolved.
An increasing number of articles shows evidence that eNO is
related to atopic asthma more than to nonatopic asthma or
atopy per se. It has been demonstrated that atopic asthmatic
children had higher geometric mean eNO levels than did non-
atopic asthmatic children, atopic nonasthmatic children, or non-
atopic nonasthmatic children, suggesting that both atopy and
asthma are important in the context of elevated eNO levels
(21). In other studies, eNO levels were significantly higher in
atopic subjects with asthma compared with levels from non-
atopic asthmatic subjects (22, 23). Similar results were ob-
tained in patients with rhinitis, whereas no difference was
found in eNO levels between atopic and nonatopic control
subjects (22). Horvath and Barnes found elevated eNO levels
in atopic asymptomatic subjects, but suggested that this find-
ing merely reflected an early stage of airway inflammation,
possibly preceding the onset of asthmatic symptoms (24). In
our study, two subjects in the control group had a positive
RAST test, but had no elevated eNO values. Thus, with refer-
ence to the suggestion of Horvath and Barnes, the presence of
elevated eNO levels in our atopic remission group might well
be due to subclinical airway inflammation. This is also sup-
ported by other studies in which a positive correlation was
reported between eNO levels and markers of eosinophilic
airway inflammation in induced sputum (9, 25). Others dem-
onstrated an association between eNO and exposure to rele-
vant allergens (26), or a reduction in eNO after antiinflamma-
tory treatment (27). These study results provide sufficient
indications that airway inflammation is significantly associated
with elevated eNO levels, thus providing a tool in monitoring
disease activity. However, a range of normality needs to be es-
tablished.
The eNO levels measured in this study tend to be some-
what lower than those measured in other studies (9, 28). This
may be caused by technical factors. It has been shown that
there is a marked flow dependence of eNO values, with lower
values measured at high flow rates and vice versa (29). We
standardized the expiratory flow as 5% of vital capacity per
second, which resulted in an expiratory flow of approximately
0.25 to 0.30 ml/min, which is higher than the flow used in some
other studies. It is not clear whether such standardization of
flow for lung volume is important when measuring eNO. It has
been demonstrated that the flow–eNO relationship differed be-
tween subjects with asthma and healthy individuals (30). This
difference is, however, of minor importance compared with the
differences we now report between the various groups.
We believe that responsiveness to AMP may serve as an in-
dicator of airway inflammation, although normal values for
bronchial AMP responses have not been determined yet. It
was demonstrated a few years ago that experimental instilla-
tion of AMP into an airway segment caused a prompt reduc-
tion in airway caliber, paralleled by a significant rise in pros-
taglandin D2, histamine, and tryptase levels in the lavage fluid,
suggestive of mast cell degranulation (31). Since mast cells
are believed to play a predominant role in asthmatic airway
inflammation, the response to AMP may reflect different as-
pects of inflammation as compared with the bronchial re-
sponse to direct stimuli, such as methacholine or histamine.
Results supporting this statement include a more pronounced
improvement of AMP responsiveness after avoidance of aller-
gen (32), and after antiinflammatory therapy (33), as com-
pared with effect on MCh or histamine responsiveness. It has
been suggested that an exaggerated airway response to direct
stimuli, such as MCh, and abnormal FEV1 values, may exist or
persist independently of “active” airway inflammation (34). It
is probable that these indices are also influenced by irrevers-
ible airway damage, caused by airway remodeling (35). Thus,
being associated with the more slowly responding elements of
inflammation within the airways. Our finding of a positive cor-
relation between response to AMP and eNO levels, but not
between responsiveness to MCh and eNO levels, is in agree-
ment with this.
Figure 3. PD20AMP (micrograms, not cumulative) values of currently
asthmatic subjects, of subjects in clinical remission of atopic asthma,
and of healthy controls. Nonresponders are arbitrarily given a value of
twice the highest dose administered. Horizontal bars represent geo-
metric mean values. The y axis shows PD20AMP values logarithmically.
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The clinical relevance of our findings is as yet unknown.
Although one would expect the degree of abnormalities to be
related to the duration of remission, a significant correlation
could not be established. Probably, when subclinical airway in-
flammation is present during adolescence, it may persist for
several years with a continuous risk of becoming clinically
manifest again. Future longitudinal studies should assess the
possible benefits of prolonged disease monitoring and antiin-
flammatory treatment during the asymptomatic phase. Also,
the question arises concerning whether indices associated with
different parts of the inflammatory process, such as eNO and
responsiveness to AMP and MCh, need to be included in the
definition of asthma remission.
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